Heat Stable Ricin Vaccine: Soligenix receives $2M in additional funding to advance development
by Press Release from Outbreak News Today on (#2TKGA)
Soligenix, Inc. announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has exercised an option for the evaluation of RiVax(R) to fund additional animal efficacy studies. The overall objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax(R), in combination with ["]
The post Heat Stable Ricin Vaccine: Soligenix receives $2M in additional funding to advance development appeared first on Outbreak News Today.